Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
FBRX Forte Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: FBRX
Price (delayed)
$12.93
Market cap
$85.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.48
Enterprise value
$39.27M
Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and
Highlights
FBRX's EPS has soared by 57% YoY and by 22% QoQ
The equity has grown by 34% YoY but it has contracted by 27% from the previous quarter
FBRX's quick ratio is down by 44% year-on-year and by 21% since the previous quarter
The net income has contracted by 36% YoY and by 23% from the previous quarter
Key stats
What are the main financial stats of FBRX
Market
Valuations
Earnings
Shares outstanding
6.58M
Market cap
$85.12M
Enterprise value
$39.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$44.92M
Net income
-$43.71M
EBIT
-$43.71M
EBITDA
-$43.67M
Free cash flow
-$34.53M
Per share
Balance sheet
Liquidity
EPS
-$9.48
EPS diluted
-$9.48
Free cash flow per share
-$3.03
Book value per share
$5.84
Revenue per share
$0
TBVPS
$4.16
Total assets
$47.46M
Total liabilities
$9.03M
Debt
$0
Equity
$38.43M
Working capital
$38.13M
Debt to equity
0
Current ratio
5.22
Quick ratio
5.08
Net debt/EBITDA
1.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-114.3%
Return on equity
-149.2%
Return on invested capital
-2,113.6%
Return on capital employed
-113.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FBRX stock price
How has the Forte Biosciences stock price performed over time
Intraday
5.55%
1 week
1.33%
1 month
52.12%
1 year
-3.72%
YTD
-43.06%
QTD
66.62%
Financial performance
How have Forte Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.92M
Net income
-$43.71M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 36% YoY and by 23% from the previous quarter
The operating income has contracted by 34% YoY and by 23% from the previous quarter
Price vs fundamentals
How does FBRX's price correlate with its fundamentals
Growth
What is Forte Biosciences's growth rate over time
Valuation
What is Forte Biosciences stock price valuation
P/E
N/A
P/B
2.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FBRX's EPS has soared by 57% YoY and by 22% QoQ
The price to book (P/B) is 121% higher than the last 4 quarters average of 1.0 but 35% lower than the 5-year quarterly average of 3.4
The equity has grown by 34% YoY but it has contracted by 27% from the previous quarter
Efficiency
How efficient is Forte Biosciences business performance
Forte Biosciences's ROIC has plunged by 108% from the previous quarter
FBRX's return on equity has dropped by 50% year-on-year and by 13% since the previous quarter
The company's return on assets fell by 33% YoY and by 11% QoQ
Dividends
What is FBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FBRX.
Financial health
How did Forte Biosciences financials performed over time
The company's total liabilities has surged by 171% YoY
FBRX's total assets is up by 48% year-on-year but it is down by 23% since the previous quarter
Forte Biosciences's debt is 100% less than its equity
The equity has grown by 34% YoY but it has contracted by 27% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.